The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Critical reviews in oncology/hematology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2008.08.002PMID 18774306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy for advanced renal cell cancer.

  2015cited by this paper
• Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

  2010cited by this paper
• Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

  2009cited by this paper
• Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)

  2008cited by this paper
• Prognostic factors and selection for clinical studies of patients with kidney cancer.

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Impact of gender in renal cell carcinoma: an analysis of the SEER database.

  2008cited by this paper
• Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America

  2008cited by this paper
• Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

  2008cited by this paper
• Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007influential reference
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007influential reference
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• 964 CLINICAL BENEFIT OF SORAFENIB IN THE ELDERLY WITH ADVANCED RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF THE APPROACHES IN RENAL CANCER GLOBAL EVALUATION TRIAL (TARGETS)

  2007cited by this paper
• Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results

  2007cited by this paper
• Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results

  2007cited by this paper
• A phase II trial of intra-patient dose escalated-sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)

  2007cited by this paper
• Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach

  2007cited by this paper
• Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN)

  2007cited by this paper
• Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients

  2007cited by this paper
• Treatment options in metastatic renal carcinoma: an embarrassment of riches.

  2006cited by this paper
• Is intravenous (iv) IL2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (MRCC) receiving a combination of IL2 and alpha interferon (IFN)? Results of the prospective randomized PERCY Duo trial.

  2006cited by this paper
• Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status

  2006influential reference
• Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996.

  1999cited by this paper

• Real-world comparison of the efficacy of first-line therapies and the influence of risk factors in advanced renal cell carcinoma

  2025cites this paper
• Prognosis improvement in elderly patients with metastatic renal cell carcinoma in the era of systemic therapy and factors affecting survival rates

  2025cites this paper
• Anemia in patients ≥ 75 years with metastatic clear cell renal cell carcinoma: an important poor prognostic factor in the international metastatic renal cell carcinoma database consortium model

  2024cites this paper
• Representation of older patients in the safety analysis of protein kinase inhibitor registration studies.

  2023cites this paper
• Anemia in patients ≥75 years with metastatic clear cell renal cell carcinoma: An important poor prognostic factor in the international metastatic renal cell carcinoma database consortium model

  2023cites this paper
• Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?

  2022cites this paper
• Systemtherapie beim metastasierten Nierenzellkarzinom

  2021cites this paper
• Kidney Cancer in Older Adults

  2020cites this paper
• Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience.

  2020cites this paper
• Integrating Geriatric Oncology into Clinical Pathways and Guidelines

  2020cites this paper
• Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity.

  2020cites this paper
• SIOG guidelines- essential for good clinical practice in geriatric oncology.

  2019cites this paper
• Uroonkologische Konzepte im Alter

  2019cites this paper
• Renal Cell Carcinoma With Extensive Tumor Thrombus Into the Inferior Vena Cava and Right Atrium in a 70-Year-Old Man

  2019influential citation
• Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology.

  2018cites this paper
• Physicians’ perspectives on defining older adult patients and making appropriate prescribing decisions

  2018cites this paper
• Asynchronous abdominal wall and sigmoid metastases in clear cell renal cell carcinoma: A case report and literature review

  2018cites this paper
• Nierenzellkarzinom beim alten und geriatrischen Patienten

  2018influential citation
• Physicians’ perspectives on defining older adult patients and making appropriate prescribing decisions

  2018cites this paper
• Adverse Drug Reactions Involving Protein Kinase Inhibitors: A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (≥ 75 years) with Cancer

  2018cites this paper
• Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis

  2018cites this paper
• Tyrosine Kinase Inhibitors in the Elderly: A Case Report and Literature Review on Toxicity Profiles

  2017cites this paper
• Nierenzellkarzinom des alten und geriatrischen Patienten

  2017influential citation
• [Renal cell carcinoma in older and geriatric patients].

  2017cites this paper
• Tyrosine Kinase Inhibitors in the Elderly: A Case Report and Literature Reviewon Toxicity Profiles

  2017cites this paper
• Sunitinib in Special Situations in their Daily Practice

  2016cites this paper
• Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice

  2016cites this paper
• Risk factors and model for predicting toxicity‐related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

  2016cites this paper
• Guía de manejo del carcinoma de células renales

  2016cites this paper
• Treatment of elderly patients with metastatic renal cell carcinoma

  2016cites this paper
• Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma

  2016cites this paper
• Treatment‐related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up‐to‐date review and meta‐analysis of clinical trials

  2015cites this paper
• Renal Cancer in the Elderly

  2015cites this paper
• Pharmacotherapy in the ageing patient: The impact of age per se (A review).

  2015cites this paper
• Современное представление об алгоритме лекарственного лечения и оптимальной последовательности использования таргетных препаратов

  2014cites this paper
• Lymphopeniaand clinical outcome ofelderlypatients treated with sunitinib for metastatic renal cell cancer

  2014cites this paper
• Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.

  2014cites this paper
• Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

  2014cites this paper
• Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.

  2014cites this paper
• GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer.

  2014cites this paper
• Safety of Sorafenib Therapy in Elderly Adults with Advanced Hepatocellular Carcinoma

  2014cites this paper
• Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.

  2014cites this paper
• Optimal management of renal cell carcinoma in the elderly: a review

  2013cites this paper
• Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.

  2013cites this paper
• Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study.

  2013cites this paper
• Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years).

  2013cites this paper
• Advanced kidney cancer: treating the elderly

  2013cites this paper
• Geriatrisches Assessment vor onkologischer Therapie

  2013cites this paper
• Sorafenib and sunitinib for elderly patients with renal cell carcinoma.

  2013cites this paper
• Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma

  2013cites this paper
• Treatment of Metastatic Kidney Cancer in the Elderly

  2013cites this paper
• Optimal management of renal cell carcinoma in the elderly: a review

  2013cites this paper
• Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma.

  2012cites this paper
• Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma

  2012cites this paper
• New Perspectives in Advanced Genitourinary Malignancies

  2012cites this paper
• Paradigm towards Tailored Therapies and Complete Responses in the Treatment of Metastatic Renal Cell Carcinoma

  2012cites this paper
• Sorafenib for the treatment of renal cancer

  2012cites this paper
• Treating patients with metastatic renal carcinoma: an escape from Phase III

  2012cites this paper
• Experience with sorafenib in the treatment of advanced renal cell carcinoma

  2012cites this paper
• Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.

  2012cites this paper
• The International Society of Geriatric Oncology conference: Paris 2011

  2012cites this paper
• Senior adult oncology.

  2012cites this paper
• Major urologic problems in geriatrics: assessment and management.

  2011cites this paper
• Pharmacotherapy of patients with metastatic renal-cell carcinoma – algorithm vs. Polish reality [Polish version: Leczenie farmakologiczne chorych na rozsianego raka nerki – algorytm a polskie realia p. 299]

  2011cites this paper
• Thérapies ciblées dans la prise en charge des cancers des patients âgés

  2011cites this paper
• A new patient‐focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options

  2011cites this paper
• Quality of Life in Elderly Patients with Urological Malignancies — A Review of Standard Questionnaires

  2011cites this paper
• Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults

  2011influential citation
• [Treatment of metastatic renal cell carcinoma].

  2011cites this paper
• Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long‐term use

  2011cites this paper
• Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study

  2011cites this paper
• Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.

  2011cites this paper
• Sequential use of targeted agents in the treatment of renal cell carcinoma.

  2011cites this paper
• Sorafenib in renal cell carcinoma.

  2011influential citation
• Experience with sorafenib and the elderly patient

  2010influential citation
• Cancer du rein : traitements anti-angiogéniques et gestion des complications. À propos d'un cas

  2010cites this paper
• Advances in renal cell carcinoma treatment

  2010influential citation
• Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients

  2010cites this paper
• How to select targeted therapy in renal cell cancer.

  2010cites this paper
• Treatment of metastatic renal cell carcinoma

  2010cites this paper
• [Renal cell carcinoma: antiangiogenic therapies and management of the complications. A case report].

  2010cites this paper
• Prolonged Response to Cytoreductive Surgery and Sunitinib in an Elderly Patient with Synchronous Multiple Metastases from Renal Cell Carcinoma

  2010cites this paper
• A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01

  2010cites this paper
• Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.

  2010cites this paper
• Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer

  2009cites this paper
• Current options in the management of advanced renal-cell carcinoma

  2009cites this paper
• Advances in geriatric oncology

  2009cites this paper
• Is age a prognostic factor for treatment outcome in renal cell cancer-A comprehensive review.

  2009cites this paper
• The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations

  2009cites this paper
• EORTC-GU group expert opinion on metastatic renal cell cancer.

  2009cites this paper
• long-term use

  2009cites this paper
• [Treatment of metastatic kidney cancer in elderly subjects].

  2009cites this paper
• EUROPEAN ASSOCIATION OF UROLOGY

  2008cites this paper
• Guidelines on Renal Cell Carcinoma

  2007cites this paper